Search Within

Roberta Zappasodi

Formats
  1. Meeting Abstract (35)
  2. Journal Article (28)
  3. Editorial (4)
  4. Review (3)
  5. Guidelines (1)
Groups
  1. Sloan Kettering Institute Postdocs (71)
  2. Department of Medicine (60)
  3. Solid Tumor Oncology Division (58)
  4. Melanoma and Immunotherapeutics Service (56)
  5. GSK Faculty (51)
  6. MSK Grad Students (21)

More Groups

People
  1. Taha Merghoub (55)
  2. Jedd Wolchok (49)
  3. Sadna Budhu (30)
  4. Cailian Liu (19)
  5. Hong Zhong (14)
  6. Levi Mark Mangarin (14)

More People

Years
  1. 2022 (15)
  2. 2021 (9)
  3. 2020 (14)
  4. 2019 (7)
  5. 2018 (10)
  6. 2017 (4)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (24)
  2. Cancer Research (7)
  3. Cancer Immunology Research (4)
  4. Journal of Immunology (4)
  5. Nature (3)
  6. Cancer Cell (2)

More Publications

Publishers
  1. Biomed Central Ltd (24)
  2. American Association for Cancer Research (12)
  3. Nature Publishing Group (8)
  4. Cell Press (5)
  5. The American Association of Immunologists, Inc (4)
  6. American Association for the Advancement of Science (3)

More Publishers

Results (71)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Apr-246 induces an increase in tumor immunogenicity in a p53 independent manner
    Meeting Abstract

    Venkatesh, D.; Michels, J.; Lu, C.; Budhu, S.; George, M.; Ouerfelli, O.; Abrahmsen, L.; Zappasodi, R.; Wolchok, J.; Merghoub, T.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • APR-246 enhances tumor immunogenicity even in the absence of p53
    Meeting Abstract

    Venkatesh, D.; Michels, J.; Liu, C.; Budhu, S.; George, M. M.; Abrahmsen, L.; Zappasodi, R.; Wolchok, J. D.; Merghoub, T.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Activating canonical p53 functions in tumor-associated macrophages improves immune checkpoint blockade efficacy
    Meeting Abstract

    Ghosh, A.; Michel, J.; Venkatesh, D.; Mezzadra, R.; Dong, L.; Samaan, F.; Gomez, R.; Suek, N.; Holland, A.; Ho, Y. J.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Editorial: Factors determining long term anti-tumor responses to immune checkpoint blockade therapy
    Editorial

    Zappasodi, R.; Cook, G. P.; Taylor, A.
    Frontiers in Immunology (2022)

    Fulltext@MSK | Save
  • Phase IB study of GITR agonist antibody TRX518 singly and in combination with gemcitabine, pembrolizumab, or nivolumab in patients with advanced solid tumors
    Journal Article

    Davar, D.; Zappasodi, R.; Wang, H.; Naik, G. S.; Sato, T.; Bauer, T.; Bajor, D.; Rixe, O.; Newman, W.; Qi, J.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade
    Journal Article

    Ghosh, A.; Michels, J.; Mezzadra, R.; Venkatesh, D.; Dong, L.; Gomez, R.; Samaan, F.; Ho, Y. J.; Campesato, L. F.; Mangarin, L.; more...
    Journal of Clinical Investigation (2022)

    Fulltext@MSK | Save
  • A decade of checkpoint blockade immunotherapy in melanoma: Understanding the molecular basis for immune sensitivity and resistance
    Review

    Huang, A. C.; Zappasodi, R.
    Nature Immunology (2022)

    Fulltext@MSK | Save
  • Fundamental immune–oncogenicity trade-offs define driver mutation fitness
    Journal Article

    Hoyos, D.; Zappasodi, R.; Schulze, I.; Sethna, Z.; de Andrade, K. C.; Bajorin, D. F.; Bandlamudi, C.; Callahan, M. K.; Funt, S. A.; Hadrup, S. R.; more...
    Nature (2022)

    Fulltext@MSK | Save
  • MAIT and Vδ2 unconventional T cells are supported by a diverse intestinal microbiome and correlate with favorable patient outcome after allogeneic HCT
    Journal Article

    Andrlová, H.; Miltiadous, O.; Kousa, A. I.; Dai, A.; DeWolf, S.; Violante, S.; Park, H. Y.; Janaki-Raman, S.; Gardner, R.; El Daker, S.; more...
    Science Translational Medicine (2022)

    Fulltext@MSK | Save
  • Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine
    Journal Article

    Gigoux, M.; Holmström, M. O.; Zappasodi, R.; Park, J. J.; Pourpe, S.; Bozkus, C. C.; Mangarin, L. M. B.; Redmond, D.; Verma, S.; Schad, S.; more...
    Science Translational Medicine (2022)

    Fulltext@MSK | Save